Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New ICG study shows blood pressure control rate improvements

CardioDynamics : 19 May, 2008  (Company News)
An independent Impedance Cardiography (ICG) clinical study has reported from a 65 physician primary care and cardiology group practice and demonstrated a 102 percent improvement in blood pressure control rates, with control rates improving from 42 percent to 88 percent when using BioZ ICG noninvasive cardiac monitoring systems from CardioDynamics
The study was presented at the Twenty-third Annual American Society for Hypertension (ASH) Scientific Meeting in New Orleans, Louisiana, USA. More than 76,000 patient visits were included in the analysis

Robert E Matthews, executive director, PriMed Physicians, Dayton Ohio, stated, 'Our physician group has set strategic goals to achieve nationally recognised levels of clinical and service quality, particularly chronic disease management including hypertension. We used a Six Sigma quality approach to develop a process for the treatment of patients diagnosed with hypertension and we incorporated the use of BioZ ICG to guide antihypertensive therapy selection in patients whose blood pressure was not at goal. Our analysis clearly and repeatedly showed that the use of ICG was a significant contributor to whether or not the patient achieved goal blood pressure and allowed us to achieve the highest known hypertension control rate of all group practices in the United States.'

Douglas Magenheim, MD, MBA, medical director for PriMed, initially piloted use of the BioZ ICG and found that it significantly improved his ability to help achieve appropriate hypertension control. Based upon his experience, the group initially included BioZ ICG in the Hypertension quality process and measured whether, in fact, it would be an effective, value added step in changing outcomes.

Mark Couch, MD, president, PriMed Physicians, stated, 'According to JNC-7 national guidelines and several other studies, approximately 31 to 34 percent of patients who have the diagnosis of hypertension are actually achieving goal blood pressure. Our group's baseline, pre-intervention results demonstrated that 42 percent of our patients were at or better than the JNC-7 goal blood pressures. This rate, while better than the national average, left great room for improvement. We are extremely pleased with the 88 percent control rates we have achieved and the fact that we appear to lead the nation in managing this very highly important disease. Our internal Six Sigma studies have repeatedly confirmed that the use of ICG was a significant tool to assist our physicians and patients to achieve blood pressure goal. Conversely, the achievement of goal blood pressure was significantly impeded when this test was not used on hypertensive patients. Therefore, we have adopted a policy as a group that our physicians shall use the Hypertension Process, including ICG, when the patient's blood pressure is not at goal.'

Multiple classes of antihypertensive medications have been identified, and more than 100 medications are available for the treatment of high blood pressure. However, improved blood pressure control has remained an elusive target despite great public and physician awareness and a large armament of antihypertensive medications with proven benefit. The number of available drugs and co-morbidities creates difficult blood pressure management decisions, especially in the patient with long-standing hypertension. ICG has emerged as a valuable new tool for diagnostic and prognostic assessment in hypertensive patients to aid therapeutic decision making.

'These are impressive, real-world results, nearly three times the national average, across a 65-plus multi-specialty physician group practice,' stated Michael K Perry, CardioDynamics' chief executive officer. 'The medical community continues to validate ICG's usefulness in physicians' diagnosis and treatment as well as patient outcomes. We remain committed to partnering with the research community to incorporate ICG into the treatment guidelines and to significantly improve outcomes for the millions of patients with high blood pressure, heart failure and other forms of cardiovascular disease.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo